Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANCICLOVIR vs AMANTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including AIDS patients.,Prevention of CMV disease in transplant recipients at risk.,Treatment of CMV pneumonitis, colitis, esophagitis, and other CMV infections in immunocompromised patients (off-label).,Treatment of herpes simplex virus (HSV) infections resistant to acyclovir (off-label).
Influenza A virus infection (prophylaxis and treatment),Parkinson's disease (symptomatic treatment),Drug-induced extrapyramidal reactions
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for Cr Cl <70 m L/min
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Ganciclovir is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Less than 1% is metabolized to 9-[(1,3-dihydroxy-2-propoxymethyl)guanine].
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism (less than 10%) with no major identified metabolites.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
1-2% bound; primarily to albumin (low binding)
60-70% bound, primarily to albumin
0.47-0.74 L/kg; indicates extensive distribution into tissues including brain, eye, and lungs
Vd: 4-10 L/kg; indicates extensive tissue binding and penetration into brain (CSF: 50-80% of plasma concentration)
Oral: 6-9% (fasting); increased to 30% with food due to enhanced absorption
Oral: 86-90%; IV: 100%
Cr Cl ≥70 m L/min: 5 mg/kg q12h (induction), 5 mg/kg q24h (maintenance); Cr Cl 50-69: 2.5 mg/kg q12h, then 2.5 mg/kg q24h; Cr Cl 25-49: 2.5 mg/kg q24h, then 1.25 mg/kg q24h; Cr Cl 10-24: 1.25 mg/kg q24h, then 0.625 mg/kg q24h; Cr Cl <10: 1.25 mg/kg 3 times/week after hemodialysis. Oral: Cr Cl ≥70: 1000 mg tid; 50-69: 1500 mg qd or 500 mg tid; 25-49: 1000 mg qd or 500 mg bid; 10-24: 500 mg qd; <10: 500 mg 3 times/week after dialysis.
Cr Cl 30-50 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 100 mg every other day; Cr Cl <15 m L/min or hemodialysis: 200 mg every 7 days.
No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction due to limited data.
No specific Child-Pugh adjustments; use caution in severe hepatic impairment due to potential toxicity.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral dosing in children ≥9 years: 1000 mg three times daily with food; for children <9 years, use weight-based: 30 mg/kg per dose (max 1000 mg) three times daily.
Influenza A prophylaxis/treatment: 1-9 years: 5 mg/kg/day (max 150 mg/day) in 2 divided doses; 10-12 years: 100 mg twice daily; 13-16 years: 100 mg twice daily. Parkinson's: not recommended.
No specific dose adjustments beyond renal function. Closely monitor renal function and adjust dose based on Cr Cl.
Use lower starting dose (100 mg daily) due to age-related renal decline; frequent monitoring for neuropsychiatric effects.
Ganciclovir is associated with granulocytopenia, anemia, and thrombocytopenia. Animal studies have shown that ganciclovir is carcinogenic, mutagenic, and causes impairment of fertility and teratogenicity. It is indicated only for the treatment of CMV retinitis and prevention of CMV disease in transplant recipients. Not approved for congenital or neonatal CMV disease.
None.
Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression, especially in patients with pre-existing cytopenias or on concomitant myelosuppressive drugs.,Renal impairment: Dose adjustment required; increased risk of toxicity in renal dysfunction.,Carcinogenicity and mutagenicity: Anticipated in humans based on animal data.,Teratogenicity: Embryotoxic and teratogenic in animals; use only if benefit outweighs risk.,Interaction with mycophenolate mofetil: May increase risk of hematologic toxicity.,Electrolyte disturbances: May cause hypocalcemia, hypokalemia, hyponatremia.,Ocular effects: Retinal detachment in patients with CMV retinitis (not directly drug-related).,Seizures and neurotoxicity: Rare, especially in patients with CNS conditions or renal impairment.
Can cause CNS effects such as confusion, hallucinations, and seizures, especially in elderly or those with renal impairment,May exacerbate psychiatric disorders,Abrupt discontinuation may precipitate parkinsonian crisis or neuroleptic malignant syndrome in patients with Parkinson's disease,Avoid in patients with uncontrolled epilepsy,Renal dose adjustment required
Hypersensitivity to ganciclovir, valganciclovir, or any component of the formulation.,Absolute neutrophil count < 500 cells/μL, platelet count < 25,000/μL, or hemoglobin < 8 g/d L (relative contraindication due to risk of worsening cytopenias).,Pregnancy (avoid unless potential benefit outweighs risk; embryotoxic in animals).
Hypersensitivity to amantadine or any component,Severe uncontrolled epilepsy,Concomitant use with live attenuated influenza vaccine (since antiviral activity may impair vaccine efficacy)
Take ganciclovir with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase drug levels (weak interaction). No specific food restrictions otherwise.
No specific food interactions. Avoid alcohol and limit caffeine intake due to potential increased CNS effects. Take with food if gastrointestinal upset occurs.
FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benefit outweighs risk. Second/third trimester: potential for bone marrow suppression and nephrotoxicity in fetus; use only if clearly needed.
FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second and third trimesters: Limited data; theoretical risk of fetal tachyarrhythmia and neurobehavioral effects. Human data insufficient to exclude risk.
Not recommended. M/P ratio unknown; ganciclovir is excreted into breast milk in rats. Potential for severe adverse effects in nursing infant (e.g., bone marrow suppression, carcinogenesis).
Amantadine is excreted into breast milk with an M/P ratio of approximately 0.5. Limited human data; potential for adverse effects in nursing infants (e.g., irritability, urinary retention). Caution advised; use only if potential benefit outweighs risk.
No specific pregnancy dosing adjustments established. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor drug levels if available. Standard dosing: 5 mg/kg IV q12h x 14-21 days (induction), then 5 mg/kg/day (maintenance). Adjust for renal function (Cr Cl). Use lowest effective dose.
No specific pregnancy-related dosing adjustments established. Pharmacokinetic changes in pregnancy (increased renal clearance) may reduce serum levels; monitor clinical response and consider dose adjustment if efficacy wanes. Maximum dose 200 mg/day.
Monitor renal function closely; dose adjustment required in renal impairment. Ganciclovir is myelosuppressive; check CBC frequently, especially in patients with neutropenia. Use with caution in patients with pre-existing cytopenias. Administer IV infusion over at least 1 hour to reduce renal toxicity. Valganciclovir, the prodrug, is only for CMV retinitis in immunocompromised patients. Always maintain adequate hydration to prevent crystalluria.
Amantadine is an antiviral and antiparkinsonian agent with NMDA receptor antagonist properties. For Parkinson's disease, it improves dyskinesias, especially levodopa-induced dyskinesias. For influenza A, it is less effective than neuraminidase inhibitors and resistance is common. Monitor for CNS effects (confusion, hallucinations, nightmares) especially in elderly or renally impaired patients. Dose adjustment required for Cr Cl <50 m L/min. Do not discontinue abruptly in Parkinson's disease due to risk of neuroleptic malignant syndrome.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Ganciclovir may lower your blood cell counts, increasing risk of infection, bleeding, or anemia. Report any signs of infection (fever, chills), unusual bruising/bleeding, or fatigue immediately.,Keep all appointments for blood tests and kidney function monitoring.,Drink plenty of fluids to prevent kidney problems.,Use effective contraception during treatment and for at least 30 days after stopping for females, and for 90 days for males; ganciclovir can harm an unborn baby.,Do not breastfeed during treatment due to potential harm to the infant.,Avoid driving or operating machinery if you experience dizziness, confusion, or seizures.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol as it may increase dizziness or confusion.,Report any unusual thoughts, hallucinations, or severe confusion to your healthcare provider immediately.,If you have Parkinson's disease, this medicine helps control symptoms but does not cure it.,If you are taking for influenza, finish the full course even if you feel better.,May cause blurred vision or dizziness; avoid driving or operating machinery until you know how it affects you.,Stay hydrated but avoid excessive caffeine as it may exacerbate side effects.
"Probenecid inhibits renal tubular secretion of ganciclovir, reducing its clearance and increasing its plasma concentration. This can potentiate the antiviral effect but also elevates the risk of dose-dependent adverse effects such as myelosuppression and nephrotoxicity. Concurrent use may require dose adjustment of ganciclovir and monitoring for toxicity."
"Combined use of ganciclovir and zidovudine results in additive myelosuppression, particularly neutropenia and anemia, due to overlapping bone marrow toxicity. This interaction increases the risk of severe hematologic adverse effects, including life-threatening infections and transfusion-dependent anemia. Patients with pre-existing cytopenias or those receiving other myelotoxic agents are at heightened risk."
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANCICLOVIR vs AMANTADINE, answered by our medical review team.
GANCICLOVIR is a Antiviral that works by Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).. AMANTADINE is a Antiviral / Antiparkinsonian that works by Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANCICLOVIR and AMANTADINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANCICLOVIR is: Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.. The standard adult dose of AMANTADINE is: 100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANCICLOVIR and AMANTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANCICLOVIR is classified as Category D/X. FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benef. AMANTADINE is classified as Category C. FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.